What is SS-31?
SS-31, also known as elamipretide, is a small synthetic peptide with an unusual address: it concentrates inside mitochondria, the structures that produce most of a cell's energy. Unlike most peptides in the regenerative conversation, it has been developed as a serious pharmaceutical candidate, with a program running all the way into phase 3 trials.
That makes SS-31 one of the most interesting case studies in this library: a mitochondrial peptide with real human trials to read, and results that genuinely differ by condition. The honest way to understand it is one indication at a time, which is how this article proceeds.
How does it work?
The target is a lipid called cardiolipin, found almost exclusively in the inner mitochondrial membrane, where it organizes the proteins of the electron transport chain, the machinery that turns nutrients into ATP. When cardiolipin is disrupted, energy production gets less efficient and the machinery leaks more damaging reactive oxygen species.
SS-31 binds cardiolipin and stabilizes that inner membrane, with the goal of keeping the energy machinery organized and efficient. A 2025 review lays out this mechanism and the trial landscape built on it. It is one of the cleanest mechanism stories in this space, and the trials exist precisely to test how far a clean mechanism carries.
Why it matters in regenerative medicine
Mitochondrial decline is one of the recurring villains of this whole library: it sits under fatigue, slow recovery, heart failure, neurodegeneration, and aging itself. Most compounds that claim to help mitochondria never leave the supplement aisle. SS-31 is the rare one that went to trial in real diseases with hard measurements, so its results, wins and misses both, teach more about mitochondrial medicine than a hundred mechanism papers.
What the trials found, condition by condition
The headline test was MMPOWER-3, a phase 3 randomized controlled trial published in Neurology in 2023 (NCT03323749): daily subcutaneous elamipretide versus placebo in primary mitochondrial myopathy, the inherited disease its mechanism most directly addresses. Its co-primary endpoints, six-minute walk distance and a fatigue score, were not clearly met. The most direct test, and a miss.
The cardiac story reads differently. A 2017 randomized placebo-controlled trial in heart failure with reduced ejection fraction found that a single high-dose intravenous infusion produced favorable reductions in left ventricular volumes with no serious adverse events, and the PROGRESS-HF phase 2 program examined ventricular function further in the same population. Encouraging structural signals, short of outcome proof.
The program keeps widening: NuPower (NCT05162768), a phase 3 in mitochondrial disease from nuclear DNA mutations, completed in 2024, and ReNEW (NCT06373731), a large phase 3 in dry age-related macular degeneration, is ongoing, extending the cardiolipin idea into the aging eye.
What people notice in practice
SS-31 circulates in longevity and biohacking circles ahead of any approval, so practice reports exist: users describe steadier energy, better exercise tolerance, and less post-exertion crash, the exact subjective territory its mechanism predicts. Labeled honestly: these are the least verifiable anecdotes in this library, because energy is the most placebo-responsive endpoint there is, and the phase 3 trial measuring exactly that construct in the sickest relevant patients did not clearly succeed.
The sourcing caution peaks here too: a peptide still in pharmaceutical development has no legitimate consumer supply chain, so gray-market vials carry all the usual questions plus a few extra.
The pros and the cons
What's promising
- A genuinely elegant mechanism: stabilizing cardiolipin, the membrane lipid the energy machinery depends on.
- Real pharmaceutical development: multiple phase 2 and phase 3 trials, a rarity in this space.
- Favorable cardiac structural findings in randomized testing, with good tolerability.
- An active, expanding program including a large phase 3 in macular degeneration.
What's uncertain
- The most direct test, phase 3 in mitochondrial myopathy, did not clearly meet its endpoints.
- Cardiac findings are structural signals, not yet outcome results.
- No approval anywhere, and no legitimate consumer supply.
- The energy and longevity uses in circulation rest on the least testable endpoints.
Worth considering
- Read this one condition by condition; a single verdict flattens what the trials actually say.
- The macular degeneration and nuclear-DNA-disease results will move the story next.
- Gray-market use of a compound mid-development stacks sourcing risk on scientific uncertainty.
- Mitochondrial complaints deserve a workup; fatigue has many causes cheaper to find than to peptide over.
Why the mixed results are informative
SS-31 is what happens when a beautiful mechanism meets hard endpoints: sometimes the tissue responds (cardiac volumes) and sometimes the disease does not budge on what patients feel (myopathy walk distance and fatigue). That split is not failure; it is information about where membrane stabilization matters most, and the ongoing trials are mapping exactly that. For readers, it is also a vaccination against mechanism-based marketing: the same cardiolipin story that sells gray-market vials did not carry its own phase 3.
What the key trials tested
Our framing rule for evidence: a trial tests one dose, one route, one population, one endpoint. Where the evidence sits:
Preclinical & practice
The energy, recovery, and longevity uses circulating ahead of approval.
Early trials
Heart failure phase 2 (single-infusion and PROGRESS-HF): favorable ventricular signals.
Late-stage trials
MMPOWER-3 (endpoints not clearly met), NuPower (completed 2024), ReNEW in macular degeneration (ongoing).
Approved uses
None yet, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
What does SS-31 actually do to mitochondria?
It binds cardiolipin, the signature lipid of the inner mitochondrial membrane, and stabilizes the membrane where the energy-producing machinery is anchored. Organized machinery runs more efficiently and leaks fewer damaging oxygen radicals. That is the mechanism; how much it changes what patients feel is exactly what the trial program is still sorting out.
Did it fail its big trial?
Its most direct one, yes, in the careful sense: MMPOWER-3 in primary mitochondrial myopathy did not clearly meet its co-primary endpoints of walk distance and fatigue. The same molecule produced favorable cardiac structural findings in randomized heart-failure testing, and two other phase 3 programs are running. Mixed by condition is the accurate summary, not failed and not vindicated.
Can I buy SS-31?
Not legitimately: it is an unapproved compound still in pharmaceutical development, so everything on the consumer market is gray-market synthesis with no verified identity, purity, or dose. That stacks sourcing risk on top of scientific uncertainty, and it is the main practical reason we treat SS-31 as one to watch rather than one to use.
What results are coming next?
Two phase 3 readouts matter most: NuPower in mitochondrial disease caused by nuclear DNA mutations, completed in 2024, and ReNEW in dry age-related macular degeneration, a large ongoing trial extending the mechanism into the aging retina. Between them, the next chapter of the cardiolipin story gets written either way.
What to take away
If you remember five things from this article, make them these:
- SS-31 targets cardiolipin, stabilizing the membrane the cell's energy machinery is built on.
- It is one of the few mitochondrial compounds with real phase 2 and phase 3 human trials.
- The results split by condition: cardiac structure responded, myopathy endpoints did not clearly move.
- Nothing is approved, and there is no legitimate consumer supply; gray-market vials carry double risk.
- Read it condition by condition, and let the ongoing phase 3 results, not the mechanism, settle the verdict.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. SS-31 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.